Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Intervalo de año de publicación
1.
Acta Cir Bras ; 31(4): 271-7, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27168540

RESUMEN

PURPOSE: T o investigate the possible protective effect of thymoquinone (TQ) in cisplatin (CP) induced myocardial injury. METHODS: A total of 28 adult male Wistar-Albino rats were randomly and equally divided into four groups as follows: Group 1 (control), Group 2 (CP at 15 mg/kg dose), Group 3 (TQ 40 mg/kg/day for two days prior to CP injection and on third day, CP at 15 mg/kg dose was intraperitoneally administered and TQ treatment continued until fifth day) and Group 4 (TQ at 40mg/kg/day dose for five days). RESULTS: There was a significant increment in CP group in terms of congestion, edema and pycnotic nuclei in myocardial fibers, comparing with other groups. TQ group exhibited significant increase in expression of antiapoptotic protein Bcl-2, comparing with CP group (p<0.05). In only CP administered group, expression of antiapoptotic protein Bcl-2 was lowest comparing with other groups. CONCLUSION: Established data indicate that cisplatin is cardiotoxic and thymoquinone may be useful in treating CP-induced cardiac injury.


Asunto(s)
Antineoplásicos/toxicidad , Antioxidantes/farmacología , Benzoquinonas/farmacología , Cardiomiopatías/inducido químicamente , Cardiomiopatías/prevención & control , Cisplatino/toxicidad , Animales , Antioxidantes/uso terapéutico , Apoptosis/efectos de los fármacos , Benzoquinonas/uso terapéutico , Cardiomiopatías/patología , Cardiotoxicidad/etiología , Cardiotoxicidad/patología , Cardiotoxicidad/prevención & control , Corazón/efectos de los fármacos , Inmunohistoquímica , Masculino , Miocardio/patología , Miocitos Cardíacos/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Proteínas Proto-Oncogénicas c-bcl-2/análisis , Proteínas Proto-Oncogénicas c-bcl-2/efectos de los fármacos , Distribución Aleatoria , Ratas Wistar , Valores de Referencia , Reproducibilidad de los Resultados , Factores de Tiempo , Resultado del Tratamiento
2.
Acta cir. bras. ; 31(4): 271-277, Apr. 2016. ilus, tab
Artículo en Inglés | VETINDEX | ID: vti-20517

RESUMEN

PURPOSE: To investigate the possible protective effect of thymoquinone (TQ) in cisplatin (CP) induced myocardial injury.METHODS:A total of 28 adult male Wistar-Albino rats were randomly and equally divided into four groups as follows: Group 1 (control), Group 2 (CP at 15 mg/kg dose), Group 3 (TQ 40 mg/kg/day for two days prior to CP injection and on third day, CP at 15 mg/kg dose was intraperitoneally administered and TQ treatment continued until fifth day) and Group 4 (TQ at 40mg/kg/day dose for five days).RESULTS:There was a significant increment in CP group in terms of congestion, edema and pycnotic nuclei in myocardial fibers, comparing with other groups. TQ group exhibited significant increase in expression of antiapoptotic protein Bcl-2, comparing with CP group (p<0.05). In only CP administered group, expression of antiapoptotic protein Bcl-2 was lowest comparing with other groups.CONCLUSION:Established data indicate that cisplatin is cardiotoxic and thymoquinone may be useful in treating CP-induced cardiac injury.(AU)


Asunto(s)
Animales , Masculino , Ratas , Nigella sativa/química , Aceites Volátiles/uso terapéutico , Plantas Medicinales , Compuestos de Platino , Cardiotoxinas , Genes bcl-2
3.
Acta cir. bras ; Acta cir. bras;31(4): 271-277, Apr. 2016. tab, graf
Artículo en Inglés | LILACS | ID: lil-781332

RESUMEN

PURPOSE: T o investigate the possible protective effect of thymoquinone (TQ) in cisplatin (CP) induced myocardial injury. METHODS: A total of 28 adult male Wistar-Albino rats were randomly and equally divided into four groups as follows: Group 1 (control), Group 2 (CP at 15 mg/kg dose), Group 3 (TQ 40 mg/kg/day for two days prior to CP injection and on third day, CP at 15 mg/kg dose was intraperitoneally administered and TQ treatment continued until fifth day) and Group 4 (TQ at 40mg/kg/day dose for five days). RESULTS: There was a significant increment in CP group in terms of congestion, edema and pycnotic nuclei in myocardial fibers, comparing with other groups. TQ group exhibited significant increase in expression of antiapoptotic protein Bcl-2, comparing with CP group (p<0.05). In only CP administered group, expression of antiapoptotic protein Bcl-2 was lowest comparing with other groups. CONCLUSION: Established data indicate that cisplatin is cardiotoxic and thymoquinone may be useful in treating CP-induced cardiac injury.


Asunto(s)
Animales , Masculino , Benzoquinonas/farmacología , Cisplatino/toxicidad , Cardiomiopatías/inducido químicamente , Cardiomiopatías/prevención & control , Antineoplásicos/toxicidad , Antioxidantes/farmacología , Valores de Referencia , Factores de Tiempo , Inmunohistoquímica , Distribución Aleatoria , Reproducibilidad de los Resultados , Benzoquinonas/uso terapéutico , Resultado del Tratamiento , Ratas Wistar , Apoptosis/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Proteínas Proto-Oncogénicas c-bcl-2/análisis , Proteínas Proto-Oncogénicas c-bcl-2/efectos de los fármacos , Miocitos Cardíacos/efectos de los fármacos , Cardiotoxicidad/etiología , Cardiotoxicidad/patología , Cardiotoxicidad/prevención & control , Corazón/efectos de los fármacos , Cardiomiopatías/patología , Miocardio/patología , Antioxidantes/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA